Clinical trial
Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM)…
NCT00402116 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00402116 |
|---|---|
| Title | Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients |
| Official title | Phase 1/2 Study of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma |
| Lead sponsor | Eli Lilly and Company, Industry |
| Collaborators | University of California, San Francisco |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Glioblastoma, Glioblastoma Multiforme, Gliosarcoma |
| Intervention type | Drug, Radiation |
| Interventions | enzastaurin, temozolomide, radiation therapy |
| Enrollment | 72 |
| Start date | Sep 1, 2006 |
| Primary completion | Dec 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Nov 22, 2006 |
| Last update posted | Aug 6, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: